Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide

Author:

Li Zhihui1,Liu Jingyan1,Ju Gehang1,Yan Keyu1,Mao Yong2,Liu Qingchun2,Yang Xinlu2,Zhang Rong3,Qiu Wen4

Affiliation:

1. School of Pharmacy Lanzhou University Lanzhou University Lanzhou China

2. Chengdu Brilliant Pharmaceutical Co., Ltd Chengdu China

3. The Laboratory of Bioanalysis Chengdu Fanweixi Pharmaceutical Technology Co., Ltd. Chengdu China

4. Phase I Clinical Unit Lanzhou University Second Hospital Lanzhou China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference20 articles.

1. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

2. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

3. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials;Marcellin P;Hepatology,2014

4. Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

5. Long term efficacy and safety of tenofovir DF (TDF) in chronic hepatitis B patients (CHB) with documented lamivudine resistance (LAM‐R): 5 year results from a randomized, controlled trial;Fung S;Hepatology,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3